Humacyte, Inc. (HUMA) Shares Decline Amid Market Upturn: Key Points to Consider
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Source: NASDAQ.COM
Stock Performance: Humacyte, Inc. (HUMA) closed at $1.77, down 4.84% from the previous day, while the S&P 500 gained 0.44%. The stock has increased by 17.72% over the past month, outperforming the Medical sector and the S&P 500.
Earnings Projections: Analysts project Humacyte's upcoming earnings per share (EPS) to be -$0.17, a 48.48% increase from last year, with annual estimates of -$0.35 EPS and $3.51 million in revenue. The company currently holds a Zacks Rank of #4 (Sell).
Analyst Views on HUMA
Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 5.40 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.100
Low
3.00
Averages
5.40
High
11.00
Current: 1.100
Low
3.00
Averages
5.40
High
11.00
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
